In BRAF-mutated metastatic melanoma, a phase I–II clinical study assess the effect of DNA methylation on tumor progression and resistance development under therapy with BRAFi and MEKi with or without decitabine (NCT01876641). Here, BRAF is linked to metastatic melanoma.